Skip to content

Source filing unavailable

Q1 2012 · —
Revenue$102.53M+101.5% vs Q1 2011+22.7% vs Q4 2011
Net Income$27.68M+26.8% vs Q1 2011−26.1% vs Q4 2011
EPS Diluted$0.48±0.0% vs Q1 2011−39.2% vs Q4 2011
Gross Profit$93,708,000+99.0%
Operating Income$35,739,000+58.1%
Operating Cash Flow$24,295,000−0.6%
Free Cash Flowderived$24,010,000−1.5%
Margins · derived
Gross margin91.4%−1.2 pt vs Q1 2011
Operating margin34.9%−9.6 pt vs Q1 2011
Net margin27.0%−15.9 pt vs Q1 2011

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2012Q1 2011Q1 2010
Revenue$102.53M$50.88M$50.88M
Net Income$27.68M$21.83M$21.83M
EPS Diluted$0.48$0.48$0.48

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR